T cell exclusion, immune privilege, and the tumor microenvironment

@article{Joyce2015TCE,
  title={T cell exclusion, immune privilege, and the tumor microenvironment},
  author={Johanna A. Joyce and Douglas T Fearon},
  journal={Science},
  year={2015},
  volume={348},
  pages={74 - 80}
}
Effective immunotherapy promotes the killing of cancer cells by cytotoxic T cells. This requires not only that cancer-specific T cells be generated, but also that these T cells physically contact cancer cells. The coexistence in some patients of cancer cells and T cells that recognize them indicates that tumors may exhibit the phenomenon of immune privilege, in which immunogenic tissue is protected from immune attack. Here, we review the evidence that stromal cells of the tumor microenvironment… Expand

Paper Mentions

Interventional Clinical Trial
According to the high expression of tumor cell-associated antigen Nectin4 in patients with solid tumors such as non-small cell lung cancer, breast cancer, ovarian cancer, bladder… Expand
ConditionsNectin4-positive Advanced Malignant Solid Tumor
InterventionBiological
Improving homing in T cell therapy.
TLDR
New possible combinatorial strategies aimed to overcome chemokine mismatch, physical and biological barriers and immunosuppression are discussed, so as to achieve more effective ACT therapies. Expand
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment
TLDR
Evidence is provided that tumor-associated macrophages (TAMs) are an important determinant of the establishment of a T cell-excluded tumor phenotype, and the reduction of macrophage-mediated T cell exclusion increases tumor surveillance by CD8 T cells and renders tumors more responsive to anti-PD-1 treatment. Expand
Suppression of T cell responses in the tumor microenvironment.
  • A. Frey
  • Biology, Medicine
  • Vaccine
  • 2015
TLDR
The contributions of inhibitory factors to tumor T cell dysfunction leading to tumor escape are reviewed and tumor-induced suppression of antitumor immune response is recognized as a significant factor contributing to cancer growth and reversal of the inhibitory influences within the tumor microenvironment is a major research objective. Expand
Immune-Suppressing Cellular Elements of the Tumor Microenvironment
TLDR
The immunosuppressive functions of the cells of the tumor microenvironment are examined and the steps of the antitumor immune reaction that, if inhibited, would diminish intratumoral T cell accumulation are discussed. Expand
Improving efficacy of cancer immunotherapy through targeting of macrophages
TLDR
In murine models of breast cancer, it is shown that the depletion of macrophages allows T cells to interact with tumor cells, a process which enhances anti-PD-1 immunotherapy, illustrating the relevance of current clinical trials combining a strategy that deplete or modulate macrophage with anti- PD-1 Immunotherapy. Expand
Mechanisms regulating T-cell infiltration and activity in solid tumors.
TLDR
Different immunotherapies and combinatorial treatment strategies that enable the immune system to overcome barriers for enhanced tumor control and improved patient outcome are summarized. Expand
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
TLDR
Advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, are summarized and possible implications for future cancer treatment are discussed. Expand
Obstacles to T cell migration in the tumor microenvironment.
TLDR
Recent advances in understanding T cell trafficking into and within tumors are focused on and possible strategies to restore a tumor microenvironment more favorable to T cell migration and functions are discussed with a special emphasis on approaches targeting the dysregulated extracellular matrix of growing tumors. Expand
The influence of microenvironment on tumor immunotherapy
TLDR
Current evidence indicates that different factors collectively constituting the unique tumor microenvironment promote immune tolerance, and these include the expression of co‐inhibitory molecules, the secretion of lactate, and competition for nutrients between tumors and immune cells. Expand
Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells
TLDR
This review will address the immunosuppressive features of the TME, which include the stroma, cytokine and chemokine milieu, suppressive regulatory cells and hypoxic conditions, which can all pose formidable barriers for the effective anti-tumor function of CAR T-cells. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 83 REFERENCES
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.
TLDR
Across multiple mouse tumor models and human tumor biopsies, the intratumoral dendritic cell (DC) populations are delineated as distinct from macrophage populations, and CD103(+) DCs are extremely sparse and yet remarkably capable CTL stimulators. Expand
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
TLDR
A unifying conceptual framework called “cancer immunoediting,” which integrates the immune system’s dual host-protective and tumor-promoting roles is discussed. Expand
Microenvironmental regulation of tumor progression and metastasis
TLDR
The paradoxical roles of the tumor microenvironment during specific stages of cancer progression and metastasis are discussed, as well as recent therapeutic attempts to re-educate stromal cells within the TME to have anti-tumorigenic effects. Expand
B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.
TLDR
Improved chemoresponsiveness was dependent on altered chemokine expression by macrophages that promoted tumor infiltration of activated CD8(+) lymphocytes via CCR5-dependent mechanisms. Expand
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
TLDR
Findings reveal that multiple cell types contribute to the immunosuppressive tumor microenvironment and will inform therapeutic cancer vaccine design. Expand
Adoptive cell transfer as personalized immunotherapy for human cancer
TLDR
The ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment. Expand
The future of immune checkpoint therapy
TLDR
The way forward for this class of novel agents lies in the ability to understand human immune responses in the tumor microenvironment, which will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients. Expand
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.
TLDR
It is shown that granulocyte-macrophage colony stimulating factor, a cytokine critical for the numeric and functional development of MDSC populations, promotes expansion of a monocyte-derived MDSCs population characterized by expression of CD11b and the chemokine receptor CCR2. Expand
Macrophage Diversity Enhances Tumor Progression and Metastasis
TLDR
There is persuasive clinical and experimental evidence that macrophages promote cancer initiation and malignant progression, and specialized subpopulations of macrophage may represent important new therapeutic targets. Expand
Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy
TLDR
Treating tumor-bearing mice with NGR-TNF enhanced the therapeutic activity of adoptive and active immunotherapy, delaying tumor growth and prolonging survival, and it is found that therapeutic effects of these combinations can be further increased by the addition of chemotherapy. Expand
...
1
2
3
4
5
...